Regulatory notice
The FDA issued a warning letter to MEDVi, LLC on February 20, 2026, citing misbranded compounded semaglutide and tirzepatide products; no close-out has been published. FDA warning letter, February 20, 2026
Verdict
Pros
- Flat $179/mo compounded semaglutide at entry dose, $299/mo for tirzepatide.
- Month-to-month cancellation with no fee.
- Two-day average time to first prescription via async intake.
- No supplement upsells in member feedback.
- Named partner pharmacies disclosed at intake.
Cons
- Higher titration doses run $199-$299/mo, the headline price does not hold.
- Compounded only, no insurance pathway for branded GLP-1.
- Transactional model with limited between-visit support.
- Newer brand than Henry Meds or Mochi, shorter operating track record.
- Not available in Louisiana or Mississippi.
Cash-pay patients who want flat predictable compounded GLP-1 pricing with no lock-in and same-week onboarding. Strong fit if you've taken GLP-1 before and want a simple ongoing prescription channel.
Insurance-pathway shoppers, patients with multiple comorbidities needing clinical depth or anyone wanting branded Wegovy or Zepbound through standard PA.
Pricing
$179/mo for compounded semaglutide at entry dose. Higher titration doses $199-$299/mo. Tirzepatide tier $299/mo flat. Includes consultation and medication shipping.
| Signup / one-time | None |
| Membership / subscription | None |
| Medication (varies by dose) | $179–$299/mo |
| All-in, lowest maintenance dose | $299/mo |
Price since we started tracking
$299/mo, held flat across 8 weekly checks since May 2026. See the full price tracker.
See how Medvi compares with every path in our GLP-1 cost guide, or check the live price index for the full chart.
Lock-in & cancellation
Month-to-month
No annual commitment. Cancel anytime online with no fee.
How to cancel: Month-to-month, no annual commitment, cancel anytime online with no fee; billed every 28 days.
Medication options
Sourced from named 503A compounding pharmacies disclosed at intake.
The FDA officially removed semaglutide from the drug-shortage list in February 2025, which narrowed the legal basis for routine 503A compounding of exact-copy semaglutide. Medvi addresses this by using a personalized-formulation model (the compound includes an additional active ingredient like vitamin B12) which is legally distinct from the FDA-approved product. The active GLP-1 molecule is the same; the regulatory framing is different. Some state pharmacy boards have tightened oversight in 2025-2026. For the full background see our compounded vs FDA-approved breakdown.
FDA-approved branded
- None offered
Compounded
- Compounded semaglutide
- Compounded tirzepatide
Other medications
- None offered
- Compounded GLP-1 carries 503A regulatory exposure; see compounded callout
Read the buyer's guide for the medications Medvi covers: compounded semaglutide, compounded tirzepatide.
The drug comparison table covers semaglutide vs tirzepatide on cost, side effects, and clinical evidence side by side.
Where it's compounded
| Pharmacy | Belmar Pharma Solutions |
| Regulatory model | 503A and 503B (patient-specific and batch outsourcing facility) |
| State | Golden and Lakewood, CO (ships 50 states on 503A path) |
| Accreditation | PCAB accredited, NABP accredited, LegitScript certified |
| Disclosure | Publicly disclosed |
| Source | Primary source → |
FDA warning letter WL-721455 (February 20, 2026) was addressed to MEDVi, LLC itself, not to the pharmacy: website content implied Medvi was the compounder of its semaglutide and tirzepatide products when it is not. Pharmacy disclosure is public; the letter documents a labeling violation and has no published close-out.
For background on 503A vs 503B regulation and how to vet a compounding pharmacy, see Which pharmacy compounds your GLP-1, and why it matters.
Onboarding experience
Time to first prescription: 2 days.
Consultation type: Asynchronous intake review by licensed clinician.
Requirements: Medical history form, photo ID, height/weight.
Medvi reviews: what members report
Members praise the flat pricing and simple intake. Common complaint is limited clinical follow-up between dose changes.
What works
- Flat pricing at every dose
- Fast 24-48 hour intake
- No supplement upsells
What to watch
- Transactional model; limited between-visit support
- Compounded-only; no insurance for branded GLP-1
- Newer brand than Mochi or Henry Meds
How we scored Medvi
Five dimensions, ten points each, weighted equally. Overall is the simple average.
Transparency
Terms
Experience
Options
Reviews
The member-reviews pillar reflects Medvi’s Trustpilot rating of 4.5/5. See it on Trustpilot →
Frequently asked questions
Is Medvi legit?
Is Medvi a scam?
Is Medvi cheaper than Mochi?
Does Medvi accept insurance?
Alternatives to Medvi
If Medvi isn't the right fit, here are three programs we'd consider as next options:
Before committing to a cash-pay path, check whether your insurance covers a GLP-1 at the payer coverage center. On Medicaid, see Medicaid GLP-1 coverage by state first. If you need PA paperwork, the prior authorization letter library has templates for all major plans. Already denied? The appeal letter library has 120 templates by denial reason.
Direct head-to-head comparisons
Learn the category before you commit
Read these before signing up for any GLP-1 telehealth program, Medvi included:
Before committing to a cash-pay path, check whether your insurance covers GLP-1s at the payer coverage center. On Medicaid? See Medicaid GLP-1 coverage by stateto confirm your state’s formulary status before choosing a cash-pay program.
Similar programs
The three programs closest to Medvi on insurance model, medication supply and overall score, for comparison before you commit.
